News

Dr Cathy Tralau-Stewart

ValiRx appoints permanent Chief Scientific Officer

MediCity

ValiRx signals launch of new strategy with Nottingham laboratories

ValiRx - Q&A Session

Videos and audiocasts

Question and Answer Videocast

ValiRx quarterly Q&A webinar: key questions answered

Kevin Cox

Meet the ValiRx team: Dr Kevin Cox

University laboratory

Accelerating early stage, academic innovation: the Cytolytix story so far

ValiRx appoints preclinical project manager to drive development of triple breast cancer treatment

webinar

Videos and audiocasts

ValiRx Q&A Live Webinar Held on 13th December 2022

webinar

ValiRx to host live Q&A shareholder webinar

Suzy Presenting at BOS Manchester 2022

ValiRx attends Biotech Outsourcing Strategies 2022

Suzanne Dilly

ValiRx CEO introduces Cytolytix at London South East webinar

Videos and audiocasts

LSE Investor Presentation Introducing Cytolytix

Mark Treharne and Cathy Tralau-Stewart at Bio-Europe

ValiRx attends Bio-Europe 2022

Suzanne Dilly - CEO ValiRx

ValiRx signs IP license agreement with King's College London to progress triple negative breast cancer treatment